Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Òåðàïèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé-òåðàïåâòîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 03.09.2009, 15:18
Àâàòàð äëÿ Tusia
Tusia Tusia âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 22.07.2006
Ãîðîä: Ìîñêîâñêàÿ îáëàñòü
Ñîîáùåíèé: 850
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 131 ðàç(à) çà 113 ñîîáùåíèé
Tusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Strix Ïîñìîòðåòü ñîîáùåíèå
Äîêòîð, çäåñü èäåò ðå÷ü íå î äèàðåå ïóòåøåñòâåííèêîâ.
- ÿ ïðåêðàñíî ïîìíþ, î ÷åì èäåò ðå÷ü
- âû õîòèòå ñêàçàòü, ÷òî ïðè äèàðåå ïóòåøåñòâåííèêîâ ìîæåò ïðèìåíÿòüñÿ íàëèäèêñîâàÿ êèñëîòà?

Öèòàòà:
À ïðè äðóãèõ êèøå÷íûõ èíôåêöèÿõ íàëèäèêñîâàÿ êèñëîòà ïðèìåíÿòüñÿ íå äîëæíà.
Àðãóìåíòèðóéòå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 03.09.2009, 16:16
Àâàòàð äëÿ Strix
Strix Strix âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 13.05.2009
Ãîðîä: Ëîçàííà, Øâåéöàðèÿ
Ñîîáùåíèé: 503
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 201 ðàç(à) çà 193 ñîîáùåíèé
Strix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Tusia Ïîñìîòðåòü ñîîáùåíèå
- ÿ ïðåêðàñíî ïîìíþ, î ÷åì èäåò ðå÷ü
Êàêèìè æå èññëåäîâàíèÿìè ïîêàçàíà ýôôåêòèâíîñòü íàëèäèêñîâîé êèñëîòû â ïîäîáíîé ñèòóàöèè?

Öèòàòà:
Ñîîáùåíèå îò Tusia Ïîñìîòðåòü ñîîáùåíèå
- âû õîòèòå ñêàçàòü, ÷òî ïðè äèàðåå ïóòåøåñòâåííèêîâ ìîæåò ïðèìåíÿòüñÿ íàëèäèêñîâàÿ êèñëîòà?
Íàëèäèêñîâàÿ êèñëîòà ÿâëÿåòñÿ îäíèì èç òðåõ ïðåïàðàòîâ, ðåêîìåíäîâàííûõ àâòîðèòåòíûì îáçîðîì îò 2005 ãîäà (íà íåãî ññûëàåòñÿ Uptodate) ïðè äèàðåå ïóòåùåñòâåííèêîâ ó äåòåé

The following antibiotic dosing is suggested in the treatment of travelers' diarrhea in children:
Drug Pediatric Dosage
Azithromycin 10 mg/kg/day orally in 2 divided doses
Ciprofloxacin (not FDA approved in patients less than 18 years of age) 20 to 30 mg/kg/day orally in 2 divided doses (MAX dose 1.5 g/day)
Nalidixic acid 55 mg/kg/day orally in 4 divided doses


Mackell, S. Traveler's diarrhea in the pediatric population: etiology and impact. Clin Infect Dis 2005; 41:S547.

Âïîñëåäñòâèè, îäíàêî, îíà è èç Uptodate èñ÷åçëà.

Öèòàòà:
Ñîîáùåíèå îò Tusia Ïîñìîòðåòü ñîîáùåíèå
- Àðãóìåíòèðóéòå.
Íåòó íè îäíîãî èññëåäîâàíèÿ, äîêàçûâàþùåãî åå ýôôåêòèâíîñòü ïî ñðàâíåíèþ ñ äðóãèìè ñðåäñòâàìè ïðè êèøå÷íûõ èíôåêöèÿõ. Íè â êàêèõ ìåæäóíàðîäíûõ ðåêîìåíäàöèÿõ ïî ëå÷åíèþ ÎÊÈ íå ôèãóðèðóåò. Ñðàâíåíèå ñ àìïèöèëëèíîì ïðè øèãåëëåçå ïîëíîñòüþ ïðîâàëèëà (Haltalin KC, Nelson JD, & Kusmiesz HT: Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child 1973; 48:305-312).
FDA îäîáðÿåò åå ïðèìåíåíèå òîëüêî ïðè èíôåêöèÿõ ìî÷åâûâîäÿùèõ ïóòåé. Ìíå ìíåíèå ýòîé îðãàíèçàöèè êàæåòñÿ äîñòàòî÷íî àâòîðèòåòíûì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 03.09.2009, 16:33
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Strix Ïîñìîòðåòü ñîîáùåíèå
Íó, äîïóñòèì, çàòÿæíîé ýíòåðîêîëèò ñ íåýôôåêòèâíîñòüþ öåôàëîñïîðèíîâ ó ðåáåíêà, ñòðàäàþùåãî íåéðîñåíñîðíîé òóãîóõîñòüþ. È â ïîñåâàõ ÷òî-íèáóäü áåòà-ëàêòàìàçîïðîäóöèðóþùåå...
Íà ýòîò ñëó÷àé åñòü íèòðîôóðàíû (íèôóðîêñàçèä) èëè ðèôàêñèìèí - â êèøå÷íèêå íå âñàñûâàþòñÿ. À åùå ëó÷øå ñíà÷àëà ñäåëàòü ïîñåâ. Ïðè âûñåâå ïðîäóöåíòîâ ÁËÐÑ(åñëè ëàáîðàòîðèÿ èõ îïðåäåëÿåò) âûõîä îäèí - êàðáàïåíåìû, âîò òîëüêî íå çíàþ, êàê ïðèñóòñòâóþùèå çäåñü êîëåãè îòíåñóòñÿ ê êàðáàïåíåìàì ïðè ýíòåðîêîëèòå... Íó, ìîæåò, ïðè ÑÏÈÄå...

Åñòü åùå âàðèàíò ïåðîðàëüíîãî ïðèìåíåíèÿ àìèíîãëèêîçèäîâ - äëÿ ñåëåêòèâíîé äåêîíòàìèíàöèè êèøå÷íèêà, íî ýòà ìåòîäèêà ñïîðíà è â íåé, êëàññè÷åñêè, èñïîëüçóåòñÿ íåîìèöèí.
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 03.09.2009, 16:56
Àâàòàð äëÿ Tusia
Tusia Tusia âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 22.07.2006
Ãîðîä: Ìîñêîâñêàÿ îáëàñòü
Ñîîáùåíèé: 850
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 131 ðàç(à) çà 113 ñîîáùåíèé
Tusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTusia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Strix Ïîñìîòðåòü ñîîáùåíèå
Êàêèìè æå èññëåäîâàíèÿìè ïîêàçàíà ýôôåêòèâíîñòü íàëèäèêñîâîé êèñëîòû â ïîäîáíîé ñèòóàöèè
Øèãåëëåç îòâå÷àåò êðèòåðèÿì "ïîäîáíîé ñèòóàöèè" (çàòÿæíîé ýíòåðîêîëèò ó ðåáåíêà)?
Òîãäà ïîæàëóéñòà:

Öèòàòà:
Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr. 1988 Nov;113(5):901-7

We compared nalidixic acid, 55 mg/kg/day, with ampicillin, 100 mg/kg/day, both given orally for 5 days, in the treatment of children with dysentery caused by shigellosis. All patients entered into the study had illness of less than 72 hours' duration and no prior allopathic drug therapy. Treatment was randomized and administered in double-blind fashion. Patients initially treated with ampicillin who were infected with a Shigella strain resistant to ampicillin were considered as a separate group (ampicillin-R). All isolates were susceptible to nalidixic acid. Similar percentages of patients treated with nalidixic acid (26/32, 81%) and with ampicillin (17/22, 77%) were clinically cured by the end of therapy; the rate in ampicillin-R (3/14, 21%) patients was significantly lower (p less than 0.001). Stool frequency in patients treated with nalidixic acid was significantly less than for ampicillin-treated or ampicillin-R patients during the final 3 study days. All patients treated with nalidixic acid and ampicillin had Shigella eradicated from their stool by day 3, compared with 77% (10/13) of ampicillin-R patients (p less than 0.05, ampicillin-R vs nalidixic acid or ampicillin). We conclude that nalidixic acid is an effective alternative to ampicillin in the treatment of shigellosis caused by nalidixic acid-susceptible strains.
À âîò ñðàâíåíèå ýôôåêòèâíîñòè íàëèäèêñîâîé êèñëîòû è îðàëüíîãî ãåíòàìèöèíà:
Öèòàòà:
Islam MR, Alam AN, Hossain MS, Mahalanabis D, Hye HK.
Double-blind comparison of oral gentamicin and nalidixic acid in the treatment of acute shigellosis in children. J Trop Pediatr. 1994 Dec;40(6):320-5

To compare the efficacy of oral gentamicin with nalidixic acid in the treatment of acute shigellosis, we studied, in a double blind-trial, 79 comparable children with bloody diarrhoea of less than 72 h duration. Of them Shigella spp. were isolated in 71 patients. Patients were randomly assigned to receive either gentamicin 30 mg/kg/day or nalidixic acid 60 mg/kg/day, both given orally in four equal doses for 5 days. Stool frequency differed significantly between the groups from day two until completion of the study. Treatment failure was observed in 14 (42 per cent) patients receiving oral gentamicin compared to none of those with nalidixic acid-sensitive strains of Shigella spp. (P = 0.0002). Although all the shigella isolates were sensitive to gentamicin in vitro, 19 (58 per cent) patients on gentamicin therapy failed to eliminate shigella organisms from stool, compared to none in the nalidixic acid treated group infected with nalidixic acid-sensitive Shigella spp. (P < 0.001). One patient in each group had a bacteriological relapse. We conclude that gentamicin given orally was therapeutically ineffective in the treatment of acute shigellosis.
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 03.09.2009, 20:48
Àâàòàð äëÿ locot
locot locot âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 10.12.2005
Ãîðîä: Êîâðîâ
Ñîîáùåíèé: 2,843
Ñêàçàë(à) ñïàñèáî: 7
Ïîáëàãîäàðèëè 897 ðàç(à) çà 874 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 4
locot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè! Ñïàñèáî çà èíòåðåñíûå ññûëêè.
Îäíàêî îé âîïðîñ áûë â ñëåäóþùåì: âîçìîæåí ëè ïðèåì îäíîé è òîé æå ëåêàðñòâåííîé ôîðìû ( âñå ê òîìó æå âàíêîìèöèíó) äëÿ ïàðåíòåðàëüíîãî è ýíòåðàëüíîãî ïðèìåíåíèÿ. Ýòî îäíà è òà æå ñóáñòàíöèÿ. Èëè äëÿ â/ì ðàñòâîðà - îäíî äëÿ ïåð îñ äðóãîå?
Âîò â ÷åì ñóòü âîïðîñà?
×òî êàñàåòñÿ ïðåèìóùåñòâ ïðèìåíåíèÿ âàíêîìèöèíà ïåð îñ ïðè ïñåâäîìåìáðíîçíîì êîëèòå - îá ýòîì íèêòî íå ñïîðèò è íå îá ýòîì ðå÷ü, óâàæàåìûé Strix.
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 03.09.2009, 21:05
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñóáñòàíöèÿ îäíà è òà æå, ðàçíèöà òîëüêî â íàïîëíèòåëÿõ, ñâÿçóþùèõ âåùåñòâàõ, âêóñîâûõ äîáàâêàõ (äëÿ òàáëåòîê).
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 04.09.2009, 05:19
DmitryTro DmitryTro âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.01.2006
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 1,071
Ñêàçàë(à) ñïàñèáî: 49
Ïîáëàãîäàðèëè 244 ðàç(à) çà 222 ñîîáùåíèé
DmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDmitryTro ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
...ïå÷àëüíî, íî "óøè ïåðîðàëüíîãî ãåíòàìèöèíà âûðîñëè" çàäîëãî äî èññëåäîâàíèé ïåîðàëüíîãî ïðèìåíåíèÿ âàíêîìèöèíà - ýòî áåçîñíîâàòåëüíî ïåðåêî÷åâàëî èç âåòåðèíàðèè, ãäå ãåíòàìèöèí (êàê äîñòóïíûé è äåøåâûé àãåíò) ïðèìåíÿåòñÿ âåñüìà øèðîêî (ïðàâäà ñ îãðàíè÷åíèåì íà 3 íåäåëè óïîòðåáëåíèÿ ìÿñà ïîñëå ãåíòàìèöèíà áåç óòî÷íåíèÿ ôîðìû).
Ìíîãî÷èñëåííûå ôîðìû äëÿ ìåñòíîãî ïðèìåíåíèÿ (ñ 70õ ïîïóëÿðíû ìåòàêðèëàòíûå ãóáêè ñ ãåíòàìèöèíîì, íå ãîâîðþ óæå î ìàçÿõ è êàïëÿõ) ñîäåðæàò íåñîïîñòàâèìûå äîçû.
Âñåãäà îáðàùàë âíèìàíèå ïîáîðíèêîâ ïåðîðàëüíîãî ãåíòàìèöèíà íà ïðîïèñàííûå èíñòðóêöèè ïðåäîñòîðîæíîñòè ìåñòíîãî ïðèìåíåíèÿ ïðè çíà÷èòåëüíûõ ðàíåâûõ ïîâåðõíîñòÿõ è äðóãèõ ñèòóàöèÿõ, êîãäà äàæå íåçíà÷èòåëüíîå ñèñòåìíîå äåéñòâèå ãóáèòåëüíî (ìèàñòåíèÿ è ò.ä.), ê òîìó æå ïðîñòî íå ìîãó ïðåäñòàâèòü ñåáå äàæå òåîðåòè÷åñêóþ íèøó ïåðîðàëüíîãî ãåíòàìèöèíà (êðîìå ñàëüìîíåëëåçà ó ñâèíåé è ãèïîòåòè÷åñêîé äåêîíòàìèíàöèè).
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 04.09.2009, 14:17
Àâàòàð äëÿ Strix
Strix Strix âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 13.05.2009
Ãîðîä: Ëîçàííà, Øâåéöàðèÿ
Ñîîáùåíèé: 503
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 201 ðàç(à) çà 193 ñîîáùåíèé
Strix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåStrix ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Tusia Ïîñìîòðåòü ñîîáùåíèå
Øèãåëëåç îòâå÷àåò êðèòåðèÿì "ïîäîáíîé ñèòóàöèè" (çàòÿæíîé ýíòåðîêîëèò ó ðåáåíêà)?
Íåò, íî ýòî åäèíñòâåííîå ïðîöèòèðîâàííîå â Ìèêðîìåäåêñå ñðàâíèòåëüíîå èññëåäîâàíèå íàëèäèêñîâîé êèñëîòû ñ äðóãèì àíòèáàêòåðèàëüíûì ñðåäñòâîì ïðè êèøå÷íîé èíôåêöèè, ÷òî è äàëî îñíîâàíèå ÔÄÀ îöåíèòü åå öåëåñîîáðàçíîñòü ïðè øèãåëëåçå ñëîâàìè:
FDA Approval: Adult, no; Pediatric, no
Efficacy: Adult, Evidence is inconclusive
Recommendation: Adult, Class III - Not Recommended
Strength of Evidence: Adult, Category C
Ïðî îñòàëüíûå êèøå÷íûå èíôåêöèè - âîâñå íè ñëîâà.
Íî ñïàñèáî çà èíòåðåñíûå ññûëêè.

Öèòàòà:
Ñîîáùåíèå îò Tusia Ïîñìîòðåòü ñîîáùåíèå
À âîò ñðàâíåíèå ýôôåêòèâíîñòè íàëèäèêñîâîé êèñëîòû è îðàëüíîãî ãåíòàìèöèíà:
ñïàñèáî. Âîò òîëüêî íè â êàêèå ðåêîìåíäàöèè ïðè øèãåëëåçå ýòî íå âûëèëîñü. Íàïðîòèâ, ó ãåíòàìèöèíà ïðè äèàðåÿõ óðîâåíü ðåêîìåíäàöèé 2á
FDA Approval: Adult, no; Pediatric, no
Efficacy: Pediatric, Evidence is inconclusive
Recommendation: Pediatric, Class IIb
Strength of Evidence: Pediatric, Category B

Öèòàòà:
Ñîîáùåíèå îò locot
Îäíàêî îé âîïðîñ áûë â ñëåäóþùåì: âîçìîæåí ëè ïðèåì îäíîé è òîé æå ëåêàðñòâåííîé ôîðìû ( âñå ê òîìó æå âàíêîìèöèíó) äëÿ ïàðåíòåðàëüíîãî è ýíòåðàëüíîãî ïðèìåíåíèÿ. Ýòî îäíà è òà æå ñóáñòàíöèÿ. Èëè äëÿ â/ì ðàñòâîðà - îäíî äëÿ ïåð îñ äðóãîå?
Öèòàòà:
Ñîîáùåíèå îò Strix Ïîñìîòðåòü ñîîáùåíèå
"...the reconstituted intravenous formulation may be administered orally if desired. If the intravenous formulation is used for oral administration, dilute in 1 ounce of water (Prod Info vancomycin hcl IV injection)"
...Reconstituted oral solutions of intravenous vancomycin are stable for at least 90 days at 0 degrees Celsius and 4 degrees Celsius without appreciable loss of potency. Although a reconstituted solution was stable for 58 days at room temperature (45 degrees Celsius), a precipitate was observed on the 6th day in the storage vials and storage at room temperature is not recommended (Mallet et al, 1982).
Èíòåðåñíî, êñòàòè, ýòî â êàêèõ êðàÿõ òàêàÿ êîìíàòíàÿ òåìïåðàòóðà
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 04.09.2009, 15:35
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Strix Ïîñìîòðåòü ñîîáùåíèå
Íàëèäèêñîâàÿ êèñëîòà ÿâëÿåòñÿ îäíèì èç òðåõ ïðåïàðàòîâ, ðåêîìåíäîâàííûõ àâòîðèòåòíûì îáçîðîì îò 2005 ãîäà (íà íåãî ññûëàåòñÿ Uptodate) ïðè äèàðåå ïóòåùåñòâåííèêîâ ó äåòåé
Èññëåäîâàíèÿ ïî íàëèäèêñîâîé ê-òå êàêèå-òî óæ î÷åíü âñå ñòàðûå...  óâàæàåìîì The Sanford guide to antimicrobial therapy 2006 íàëèäèêñîâàÿ ê-òà íå óïîìèíàåòñÿ âîîáùå. À äëÿ ëå÷åíèÿ äèàððåè ïóòåøåñòâåííèêîâ ïðåïàðàò ïåðâîãî ðÿäà - ëåâîôëîêñàöèí (èëè öèïðîôëîêñàöèí "or otherFQ"), àëüòåðíàòèâíûå ïðåïàðàòû (Peds & pregnancy) - àçèòðîìèöèí èëè ðèôàêñèìèí.
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 04.09.2009, 15:52
Àâàòàð äëÿ Dr.
Dr. Dr. âíå ôîðóìà
Ïî÷åòíûé ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.07.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 10,123
Ïîáëàãîäàðèëè 446 ðàç(à) çà 427 ñîîáùåíèé
Dr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
×èòàë Ñýíôîðäñêîå ðóêîâîäñòâî 2006 ãîäà âåñüìà ïëîòíî, ñîìíåâàþñü, ÷òî òàì ñîâåòóþò ëåâîôëîêñàöèí ïðè äèàðåå ïóòåøåñòâåííèêîâ. Ñêîðåå öèïðî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 04.09.2009, 18:36
Àâàòàð äëÿ locot
locot locot âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 10.12.2005
Ãîðîä: Êîâðîâ
Ñîîáùåíèé: 2,843
Ñêàçàë(à) ñïàñèáî: 7
Ïîáëàãîäàðèëè 897 ðàç(à) çà 874 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 4
locot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìålocot ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Çà "the reconstituted intravenous formulation may be administered orally if desired. If the intravenous formulation is used for oral administration, dilute in 1 ounce of water (Prod Info vancomycin hcl IV injection)" - ñïàñèáî,óâàæàåìûé Strix.
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 04.09.2009, 19:54
Àâàòàð äëÿ Tihoma
Tihoma Tihoma âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 11.08.2009
Ãîðîä: Ñ-Ïåòåðáóðã
Ñîîáùåíèé: 2,188
Ñêàçàë(à) ñïàñèáî: 13
Ïîáëàãîäàðèëè 630 ðàç(à) çà 588 ñîîáùåíèé
Tihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTihoma ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Dr. Ïîñìîòðåòü ñîîáùåíèå
×èòàë Ñýíôîðäñêîå ðóêîâîäñòâî 2006 ãîäà âåñüìà ïëîòíî, ñîìíåâàþñü, ÷òî òàì ñîâåòóþò ëåâîôëîêñàöèí ïðè äèàðåå ïóòåøåñòâåííèêîâ. Ñêîðåå öèïðî.
×èòàéòå åùå ïëîòíåå! Ñåðüåçíî, ïðåïàðàò âûáîðà - Ëåâîôëîêñàöèí. Ñàì óäèâèëñÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 15:31.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.